Wednesday, 26 August 2026European Markets

SEQUANA MEDICAL Stock Bearish Momentum With A 11% Fall So Far Today

Loading stream...

(VIANEWS) - Shares of SEQUANA MEDICAL (BEL 20: SEQUA.BR) slid by a staggering 11.59% to €3.05 at 14:23 EST on Wednesday, following the last session's upward trend. BEL 20 is falling 0.51% to €3,806.44, following the last session's downward trend. This seems, up to now, a somewhat negative trend exchanging session today.

SEQUANA MEDICAL's last close was €5.06, 32.53% under its 52-week high of €7.50.

About SEQUANA MEDICAL

Sequana Medical NV, a commercial stage medical device company, engages in the development of platform for the treatment of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; Direct Sodium Removal (DSR) for the treatment of persistent congestion due to heart failure; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with fluid overload due to heart failure. It operates in Belgium, Germany, France, Switzerland, and internationally. The company was founded in 2006 and is headquartered in Ghent, Belgium.

Earnings Per Share

As for profitability, SEQUANA MEDICAL has a trailing twelve months EPS of €-1.29.

Yearly Top and Bottom Value

SEQUANA MEDICAL's stock is valued at €3.05 at 14:23 EST, way below its 52-week low of €4.82.

More news about SEQUANA MEDICAL (SEQUA.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com